Recent Quotes (30 days)

You have no recent quotes
chg | %

Atrium Innovations Inc.  

(Public, TSE:ATB)   Watch this stock  
Find more results for atb
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 11.51 - 24.50
Open     -
Vol / Avg. 0.00/320,932.00
Mkt cap 753.24M
P/E 0.00
Div/yield     -
EPS 1.25
Shares     -
Beta 0.38
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 8.93% 8.05%
Operating margin 17.01% 11.36%
EBITD margin - 17.28%
Return on average assets 5.11% 4.26%
Return on average equity 9.10% 8.20%
Employees 1,100 -
CDP Score - -


11405, boulevard du Parc-Technologique
+1-514-2056240 (Phone)
+1-418-6520151 (Fax)

Website links


Atrium Innovations Inc. (Atrium) is a Canada-based company engaged in the development, manufacturing, and commercialization of dietary supplements endorsed by health professionals. The Company owns more than 16 brands of products which are distributed mainly in the healthcare practitioner and health food and specialized store channels in more than 35 countries, with a primary focus in North America and Europe. The Company manufactures and markets more than 2,000 health and nutrition finished products. The products are generated primarily from natural sources and include vitamins, minerals and specialized products such as enzymes, probiotics and omega-3. In October 2013, the Company announced that it has acquired 70% interest of Mucos Pharma CZ s.r.o. In February 2014, Atrium Innovations Inc announced the completion of the acquisition of Atrium by corporations backed by the Permirafunds.